Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 6/20 | 0.47 |
| ▸ | MMP2 | P08253 | 8/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MMP3 | P08254 | 4/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20183913 | 0.84 | MMP13 (0.50) | MMP13MMP2CA12CA1CA2 | |
| SCHEMBL20183926 | 0.80 | CA12 (0.45) | MMP13MMP2CA12CA1CA2 | |
| SCHEMBL20183895 | 0.79 | MMP13 (0.51) | MMP13MMP2NPSR1MMP3MMP9 | |
| SCHEMBL7021143 | 0.75 | NPSR1 (0.59) | CA12CA1CA2ADRB2ADRB1 | |
| SCHEMBL8277063 | 0.75 | MMP13 (0.60) | MMP13MMP2NPSR1MMP3MMP9 | |
| SCHEMBL5649934 | 0.72 | NPSR1 (0.65) | MMP13MMP2NPSR1MMP9ALDH1A1 | |
| SCHEMBL3017227 | 0.72 | MMP2 (0.60) | MMP13MMP2CA12CA1CA2 | |
| SCHEMBL6500063 | 0.70 | CA2 (0.62) | MMP13MMP2CA12CA1CA2 | |
| SCHEMBL20183923 | 0.70 | LMNA (0.56) | ALDH1A1KMT2A | |
| SCHEMBL27214045 | 0.70 | NPSR1 (0.54) | NPSR1ALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349874-B | Compound having BLT inhibitory activity and composition for preventing or treating inflammatory disease comprising the same as active ingredient | 东国大学校产学协力团 | 2021-07-27 | — | — | CN | disclosed |
| US-10766857-B2 | Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2020-09-08 | — | — | US | disclosed |
| EP-3327000-B1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | UNIV DONGGUK IND ACAD COOP (KR) | 2020-09-02 | — | — | EP | disclosed |
| US-20190071395-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-03-07 | — | — | US | disclosed |
| US-10179764-B2 | Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-01-15 | — | — | US | disclosed |
| US-20180201573-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2018-07-19 | — | — | US | disclosed |
| EP-3327000-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201573-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | LTB4R2, CYSLTR2, LTB4R | MMP13 756/4885MMP2 868/4885CA12 4039/4885 |
| US-10766857-B2 | Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient | LTB4R2, CYSLTR2, LTB4R | MMP13 665/4885MMP2 859/4885CA12 4003/4885 |
| US-10179764-B2 | Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient | LTB4R2, CYSLTR2, LTB4R | MMP13 665/4885MMP2 859/4885CA12 4003/4885 |
| US-20190071395-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | LTB4R2, CYSLTR2, LTB4R | MMP13 756/4885MMP2 868/4885CA12 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.